Alzheimer's Disease Peripheral Immune Multi-Omics and Clinical Validation Data

A 1.5 MB Excel file published on figshare in April 2026 by author Shi Lv. It contains results from a multi-omics study investigating molecular drivers of Alzheimer's disease-associated peripheral immune dysregulation. The data integrates findings from a large-scale GWAS meta-analysis (n = 894,710), Mendelian randomization, single-cell RNA-seq, and clinical validation in the ADNI and AddNeuroMed cohorts.

Use Cases

• Prioritizing causal genes for Alzheimer's disease based on integrated GWAS and cis-eQTL data.
• Validating gene expression associations with cognitive decline and disease progression using clinical cohort data like MMSE scores and MCI-to-AD conversion.
• Analyzing epigenetic regulation of candidate genes using identified methylation probes and their correlation with mRNA expression.
• Investigating relationships between prioritized genes and peripheral immune cell profiles, such as neutrophil and lymphocyte proportions.
• Cross-cohort replication of transcriptomic findings for Alzheimer's disease biomarker validation.

Strengths

• Integrates findings from a large-scale GWAS meta-analysis involving 894,710 individuals.
• Includes multi-dimensional clinical validation from the ADNI cohort, covering gene expression, CSF biomarkers, cognitive measures, and survival analysis.
• Provides independent cross-cohort transcriptomic replication in the AddNeuroMed cohort.
• Results are supported by specific statistical evidence, such as ANOVA P=0.0023 for PTK2B and Cox HR=1.741 for MCI-to-AD conversion prediction.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain analyses.
• The dataset is small (1.5 MB), suggesting it contains summary results rather than raw multi-omics data.

Provenance

Source

figshare, author Shi Lv.

Collection Method

Generated through integrated analysis of GWAS, multi-omics Mendelian randomization, single-cell transcriptomics, and clinical cohort validation.

Time Range

Study period not specified; dataset reflects analysis results.

Freshness

Last updated 2026-04-13 05:45:58.

Geography

Geographic coverage of the ADNI and AddNeuroMed cohorts is not specified.